PAMELOR Drug Patent Profile
✉ Email this page to a colleague
When do Pamelor patents expire, and what generic alternatives are available?
Pamelor is a drug marketed by Specgx Llc and is included in two NDAs.
The generic ingredient in PAMELOR is nortriptyline hydrochloride. There are twelve drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the nortriptyline hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Pamelor
A generic version of PAMELOR was approved as nortriptyline hydrochloride by DR REDDYS LABS SA on March 30th, 1992.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PAMELOR?
- What are the global sales for PAMELOR?
- What is Average Wholesale Price for PAMELOR?
Summary for PAMELOR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 42 |
| Clinical Trials: | 8 |
| Patent Applications: | 4,143 |
| Drug Prices: | Drug price information for PAMELOR |
| What excipients (inactive ingredients) are in PAMELOR? | PAMELOR excipients list |
| DailyMed Link: | PAMELOR at DailyMed |
Recent Clinical Trials for PAMELOR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Institute of Mental Health (NIMH) | Phase 4 |
| Centre for Addiction and Mental Health | Phase 4 |
| National Cancer Institute (NCI) | Phase 1 |
Pharmacology for PAMELOR
| Drug Class | Tricyclic Antidepressant |
US Patents and Regulatory Information for PAMELOR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Specgx Llc | PAMELOR | nortriptyline hydrochloride | CAPSULE;ORAL | 018013-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Specgx Llc | PAMELOR | nortriptyline hydrochloride | CAPSULE;ORAL | 018013-003 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Specgx Llc | PAMELOR | nortriptyline hydrochloride | CAPSULE;ORAL | 018013-002 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PAMELOR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Specgx Llc | PAMELOR | nortriptyline hydrochloride | CAPSULE;ORAL | 018013-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Specgx Llc | PAMELOR | nortriptyline hydrochloride | CAPSULE;ORAL | 018013-003 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Specgx Llc | PAMELOR | nortriptyline hydrochloride | SOLUTION;ORAL | 018012-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PAMELOR
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
